![]() ![]() "The productivity of our collaboration with Shire has presented exciting product development opportunities in previously untapped target territory", said Debbie Allen, Senior VP Business Development of argenx. ![]() : ARGX /ISIN: NL0010832176 argenx announces extension of therapeutic antibody alliance with Shire Breda, the Netherlands / Ghent, Belgium - argenx (Euronext Brussels: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced the extension of its strategic partnership with Shire plc (NASDAQ: SHPG) to advance the discovery and development of novel human therapeutic antibodies for diverse rare and unmet diseases for a further year until May 30, 2018. Published: 07:00 CET 27-02-2017 /GlobeNewswire /Source: argenx N.V. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |